Novartis reports a robust 11% net revenue growth for Q2 2024, driven by strong product performance and strategic acquisitions in oncology.

Information on the Target

Novartis AG, a prominent player in the pharmaceutical industry, has reported strong financial results for the second quarter (T2) of 2024, showcasing a net revenue increase of 11% (constant currency 1, 9% USD) along with a core operating profit surge of 19% (constant currency, 17% USD). This growth is driven by robust performance across key products, notably Entresto (+28% constant currency), Kesimpta (+65% constant currency), and other important therapies.

Furthermore, the company has highlighted significant achievements in regulatory approvals for its innovative products. For instance, Fabhalta (iptacopan) has been approved in the EU, Japan, and China for treating Hemoglobinuria, while Lutathera is now FDA-approved for pediatric applications in treating specific gastroenteropancreatic tumors. These advancements position Novartis favorably within the pharmaceutical landscape.

Industry Overview in the Target’s Specific Country

The pharmaceutical industry in Switzerland, where Novartis is headquartered, is recognized for its innovation and growth potential. With a robust regulatory framework and support for research and development (R&D), the country